 |
|
An Update on Contraception in Polycystic Ovary Syndrome
Seda Hanife Oguz, Bulent Okan Yildiz
Endocrinol Metab. 2021;36(2):296-311. Published online 2021 Apr 15 DOI: https://doi.org/10.3803/EnM.2021.958
|
|
Citations to this article as recorded by
 Current and emerging drug treatment strategies for polycystic ovary syndrome
Nafiye Helvaci, Bulent Okan Yildiz
Expert Opinion on Pharmacotherapy.2023; 24(1): 105. CrossRef Investigation of taste function and eating behavior in women with polycystic ovary syndrome
Sila Cetik, Aylin Acikgoz, Bulent Okan Yildiz
Appetite.2022; 168: 105776. CrossRef microRNAs and long non‐coding RNAs as biomarkers for polycystic ovary syndrome
Mona Tamaddon, Mostafa Azimzadeh, Seyed Mohammad Tavangar
Journal of Cellular and Molecular Medicine.2022; 26(3): 654. CrossRef Effect of orlistat during individualized comprehensive life-style intervention on visceral fat in overweight or obese PCOS patients
Min Min, Xiangyan Ruan, Husheng Wang, Jiaojiao Cheng, Suiyu Luo, Zhongting Xu, Meng Li, Alfred Otto Mueck
Gynecological Endocrinology.2022; 38(8): 676. CrossRef Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT
Renyuan Li, Tingting Mai, Siyuan Zheng, Ying Zhang
Archives of Gynecology and Obstetrics.2022; 306(5): 1711. CrossRef Oral contraceptives and stroke: Foes or friends
Varun Reddy, Megan Wurtz, Shahil H. Patel, Micheline McCarthy, Ami P. Raval
Frontiers in Neuroendocrinology.2022; 67: 101016. CrossRef
|